Safety and Efficacy of Oral VV116 vs Placebo in Patients With Mild to Moderate COVID-19 in China
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Infectious Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
Lancet Infect Dis 2023 Nov 22;[EPub Ahead of Print], X Fan, X Dai, Y Ling, L Wu, L Tang, C Peng, C Huang, H Liu, H Lu, X Shen, W Zhang, F Wang, G Li, M Li, Y Huang, H Zhang, M Li, F Ren, Y Li, C Liu, Z Zhou, W Sun, Y Yi, D Zhou, H Gao, Q Pan, H Liu, J Zhao, Z Ding, Y Ma, W Li, Q Wang, X Wang, Y Bai, X Jiang, J Ma, B Xie, K Zhang, L LiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.